tiprankstipranks
Trending News
More News >
Formycon AG (DE:FYB)
XETRA:FYB

Formycon AG (FYB) AI Stock Analysis

Compare
22 Followers

Top Page

DE

Formycon AG

(XETRA:FYB)

Rating:57Neutral
Price Target:
€28.00
▼(-5.41%Downside)
Formycon AG's overall score reflects challenges in profitability and valuation, with negative earnings and absent dividend yield being significant factors. The stock's short-term technical indicators show some positive momentum, but longer-term trends remain bearish. The company's strong balance sheet provides a degree of financial stability.
Positive Factors
Cost Reduction
Phase 1 trial of FYB206 underway with the U.S. FDA indicating no need for a Phase 3 trial, potentially reducing costs.
Market Entry
FYB202/Otulfi commercially launched in the U.S. and EU at higher-than-expected price discount.
Regulatory Milestone
The U.S. FDA has provisionally determined that Otulfi would be interchangeable with the reference drug Stelara, which is a positive development for market penetration.
Negative Factors
Market Strategy
U.S. marketing of FYB201 was paused by Sandoz, affecting revenue.
Price Pressure
The company provided an update on higher-than-expected price discounts for FYB202 and FYB201.
Revenue Miss
Total revenue was €5.3M, missing our projection of €14.0M.

Formycon AG (FYB) vs. iShares MSCI Germany ETF (EWG)

Formycon AG Business Overview & Revenue Model

Company DescriptionFormycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials. The company is also developing FYB206; and FYB207, an antiviral drug for the treatment of COVID-19. It has a collaboration agreement with Leukocare AG to develop stable formulations for various candidates in its product pipeline. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.
How the Company Makes MoneyFormycon AG generates revenue through the development and commercialization of biosimilars, which are biological products highly similar to already approved reference medicines. The company's primary revenue streams include licensing agreements, development partnerships, and product sales. Formycon collaborates with various pharmaceutical companies to co-develop biosimilars, sharing the risks and profits associated with bringing these products to market. Additionally, Formycon earns milestone payments and royalties through these strategic partnerships, contributing significantly to its earnings. The company's focus on high-demand therapeutic areas and adherence to regulatory standards further bolster its revenue potential.

Formycon AG Financial Statement Overview

Summary
Formycon AG's financial performance is mixed. While the balance sheet is stable with a strong equity base and low leverage, profitability and cash flow generation are concerning. Negative profitability metrics and declining revenue growth are significant issues, although external financing has improved the cash position.
Income Statement
62
Positive
Formycon AG demonstrates volatile revenue trends with a notable decline from 2023 to 2024. The company faces profitability challenges, evidenced by negative EBIT and net income margins in 2024. Despite this, the company experienced strong EBITDA performance in 2023, indicating potential operational efficiency. However, the negative net profit margin and declining revenue growth are areas of concern.
Balance Sheet
75
Positive
The company's balance sheet shows a strong equity base with a healthy equity ratio, reflecting financial stability. The debt-to-equity ratio is low, suggesting conservative leverage usage. However, the declining stockholders' equity from 2023 to 2024 could indicate potential risk. Return on equity is negative in 2024 due to net losses, which is a downside.
Cash Flow
58
Neutral
Operating cash flows are consistently negative, highlighting challenges in generating cash from operations. Free cash flow is also negative, which may affect liquidity. Despite negative cash flows, the company has managed to improve its cash position through financing activities, which could provide short-term relief.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue69.67M77.70M42.50M36.61M34.23M
Gross Profit14.83M23.30M12.07M10.11M-2.19M
EBITDA-4.10M81.05M51.53M-12.42M-5.90M
Net Income-125.67M75.80M35.99M-13.29M-5.93M
Balance Sheet
Total Assets771.72M890.36M853.70M70.72M75.60M
Cash, Cash Equivalents and Short-Term Investments41.84M27.04M9.82M25.18M42.25M
Total Debt10.59M29.49M49.31M5.28M4.98M
Total Liabilities309.87M387.61M497.12M14.82M7.56M
Stockholders Equity461.84M502.75M356.58M55.89M68.04M
Cash Flow
Free Cash Flow-53.16M-30.60M-45.75M-14.48M-5.86M
Operating Cash Flow-23.22M-9.85M-18.99M-13.54M-5.21M
Investing Cash Flow-1.46M-17.38M-37.07M-3.93M-650.00K
Financing Cash Flow39.48M44.44M40.85M491.00K25.75M

Formycon AG Technical Analysis

Technical Analysis Sentiment
Positive
Last Price29.60
Price Trends
50DMA
24.66
Positive
100DMA
27.60
Positive
200DMA
39.68
Negative
Market Momentum
MACD
0.90
Negative
RSI
68.18
Neutral
STOCH
57.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:FYB, the sentiment is Positive. The current price of 29.6 is above the 20-day moving average (MA) of 26.98, above the 50-day MA of 24.66, and below the 200-day MA of 39.68, indicating a neutral trend. The MACD of 0.90 indicates Negative momentum. The RSI at 68.18 is Neutral, neither overbought nor oversold. The STOCH value of 57.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:FYB.

Formycon AG Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
DEFYB
57
Neutral
€499.02M5.89-26.06%-10.32%-250.76%
46
Neutral
C$189.62M-4.26-8.56%3.09%13.57%-1.98%
€1.44B61.76-4.72%0.16%
€1.44B44.66-4.72%0.27%
€331.86M20.656.73%2.02%
$367.03M22.952.99%
DEPSG
75
Outperform
€338.40M16.8348.46%1.81%13.80%10.94%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:FYB
Formycon AG
29.00
-24.80
-46.10%
GB:0N6Z
Biotest
41.20
-1.80
-4.19%
GB:0N70
Biotest
29.60
5.60
23.33%
GB:0RAR
STRATEC Biomedical
27.10
-19.23
-41.51%
MEDOF
Medios AG
14.54
-3.01
-17.15%
DE:PSG
PharmaSGP Holding SE
28.40
6.24
28.16%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 25, 2025